Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall

Insulet cut its annual sales growth forecast, citing a weaker second half of 2026 with particular softness in U.S. Omnipod pump sales. Shares fell more than 12% pre-market on the guidance downgrade, signaling a meaningful negative read-through for near-term revenue expectations.

Analysis

Insulet cut its annual sales growth forecast, citing a weaker second half of 2026 with particular softness in U.S. Omnipod pump sales. Shares fell more than 12% pre-market on the guidance downgrade, signaling a meaningful negative read-through for near-term revenue expectations.